Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA

Trial Profile

For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs PSMA 617 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Interim results (n=50) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 According to Endocyte media release, data from this trial was presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 09 May 2018 Results presented in an Endocyte media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top